- Home
- MCRB vs OBIO Comparison
MCRB vs OBIO Comparison
Compare MCRB & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- OBIO
- Stock Information
- Founded
- MCRB 2010
- OBIO 2017
- Country
- MCRB United States
- OBIO United States
- Employees
- MCRB N/A
- OBIO N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- MCRB Health Care
- OBIO Health Care
- Exchange
- MCRB Nasdaq
- OBIO Nasdaq
- Market Cap
- MCRB 141.9M
- OBIO 151.3M
- IPO Year
- MCRB 2015
- OBIO N/A
- Fundamental
- Price
- MCRB $0.37
- OBIO $2.85
- Analyst Decision
- MCRB Hold
- OBIO Strong Buy
- Analyst Count
- MCRB 5
- OBIO 5
- Target Price
- MCRB $4.00
- OBIO $15.00
- AVG Volume (30 Days)
- MCRB 1.3M
- OBIO 69.1K
- Earning Date
- MCRB 05-07-2025
- OBIO 05-12-2025
- Dividend Yield
- MCRB N/A
- OBIO N/A
- EPS Growth
- MCRB N/A
- OBIO N/A
- EPS
- MCRB 0.00
- OBIO N/A
- Revenue
- MCRB N/A
- OBIO $2,638,000.00
- Revenue This Year
- MCRB N/A
- OBIO $27.37
- Revenue Next Year
- MCRB N/A
- OBIO $42.68
- P/E Ratio
- MCRB $474.36
- OBIO N/A
- Revenue Growth
- MCRB N/A
- OBIO N/A
- 52 Week Low
- MCRB $0.46
- OBIO $2.49
- 52 Week High
- MCRB $1.53
- OBIO $8.87
- Technical
- Relative Strength Index (RSI)
- MCRB 28.34
- OBIO 36.86
- Support Level
- MCRB $0.36
- OBIO $2.75
- Resistance Level
- MCRB $0.67
- OBIO $3.26
- Average True Range (ATR)
- MCRB 0.07
- OBIO 0.48
- MACD
- MCRB -0.02
- OBIO -0.01
- Stochastic Oscillator
- MCRB 2.71
- OBIO 16.82
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.